Freeline Therapeutics Ltd. has topped up an original series C financing with a further $80m from specialist global institutional investors for a total of $120m. This will give the gene therapy specialist an extended financial runway for advancing its lead program in hemophilia B into a pivotal trial next year and its Phase I/II clinical program for Fabry disease as well as progressing its pipeline for Gaucher disease and hemophilia A, the UK-based group’s CEO told Scrip.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?